The author says they searched the phase three results for a catch and found none, and explains why the strong numbers still worry them.
Recap by typeshit. Post by Facebook on Facebook.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
The actor says quitting alcohol in 2007 didn't fix his relationship with food, and his weight eventually neared 400 pounds.
People familiar with the matter say the plan under review includes more safeguards for patients than first expected. A policy step worth watching.
Loading…